Skip to content

Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine.

Andrew Harkin, Eamonn Shanahan, John P Kelly, Thomas J. Connor

The European journal of neuroscience August 2003 DOI: 10.1046/j.1460-9568.2003.02802.x (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Preclinical experimental study Peer reviewed
Population Rats
Interventions MDA Fluoxetine
Dose MDA 7.5 mg/kg i.p. twice daily for 4 days; fluoxetine 5 or 20 mg/kg i.p. x 3
Duration 4 days MDA pretreatment, followed by 4-week washout, then fluoxetine administration and testing
Measures modified rat forced-swimming test, 5-HIAA:5-HT ratio, [3H]paroxetine binding
Topics Serotonin
Key findings Prior MDA exposure attenuates fluoxetine-induced swimming behaviour and reduces fluoxetine's ability to lower serotonin metabolism in rat brain, suggesting diminished antidepressant responsiveness.

Abstract

The effect of prior exposure to methylenedioxyamphetamine (MDA) on behavioural and neurochemical responses to fluoxetine were assessed in a rat model of antidepressant action. MDA (7.5 mg/kg, i.p.) was administered to rats twice daily for 4 consecutive days, and 4 weeks later the behavioural effect of fluoxetine (5 or 20 mg/kg; i.p. x 3) was examined in the modified rat forced-swimming test. In addition, the ability of fluoxetine to reduce serotonin (5-HT) metabolism was measured as an index of its efficacy in inhibiting 5-HT reuptake in vivo. In vehicle-treated rats, fluoxetine (5 and 20 mg/kg) produced a characteristic increase in swimming behaviour in the forced-swimming test. In contrast, fluoxetine-induced swimming was markedly attenuated in MDA-treated rats. MDA pretreatment resulted in 5-HT nerve terminal degeneration, indicated by reduced 5-HT and 5-HIAA concentrations in the frontal cortex, amygdala and hippocampus, and reduced [3H]paroxetine binding in the frontal cortex. In vehicle-treated rats, fluoxetine (5 and 20 mg/kg) decreased 5-HT metabolism (5-HIAA : 5-HT ratio) in the frontal cortex, amygdala and hippocampus. MDA pretreatment attenuated the ability of fluoxetine to reduce 5-HT metabolism in all brain regions examined. These findings are the first to demonstrate that prior exposure to the methylenedioxy-substituted amphetamine MDA results in diminished responsiveness to the antidepressant fluoxetine.